stockportfolio.pro
Xencor, Inc. (XNCR)
Healthcare · Biotechnology · NasdaqGM
Xencor, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $109.02M | $46.15M | $40.60M | $156.70M | $122.69M | $275.11M | $164.58M | $168.34M | $110.49M | $125.58M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $45.13M | $-38.49M | $-70.41M | $26.88M | $-69.33M | $82.63M | $-55.18M | $-126.09M | $-232.62M | $-91.92M |
| Net margin | 41.4% | -83.4% | -173.4% | 17.2% | -56.5% | 30.0% | -33.5% | -74.9% | -210.5% | -73.2% |
Source: Xencor, Inc. SEC filings (10-K). 14 years of history available in the interactive view.
Explore 14 years of Xencor, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track XNCR in your portfolio →
About Xencor, Inc.
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.
Xencor, Inc. — frequently asked questions
What is Xencor, Inc.'s revenue?
Xencor, Inc. (XNCR) reported revenue of $125.58M for fiscal year 2025, up 13.7% from the prior year, according to its SEC filings.
Is Xencor, Inc. profitable?
No — XNCR reported a net loss of $-91.92M in fiscal 2025.
What is XNCR's P/E ratio?
Xencor, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Xencor, Inc. growing?
XNCR's revenue grew at roughly 0.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Xencor, Inc.'s official SEC filings (10-K and 10-Q), covering 14 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.